SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,678,964,770 |
| Positions | 33 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| RELAY THERAPEUTICS INC | RLAY | COM | $224,520,000 | 12,000,000 |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $166,206,250 | 3,275,000 |
| ALKERMES PLC | ALKS | SHS | $157,185,000 | 3,000,000 |
| COGENT BIOSCIENCES INC | COGT | COM | $118,035,000 | 3,050,000 |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $101,474,000 | 5,650,000 |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $94,080,000 | 2,000,000 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $75,177,661 | 846,786 |
| ALTO NEUROSCIENCE INC | ANRO | COM SHS | $71,865,142 | 2,723,196 |
| TANGO THERAPEUTICS INC | TNGX | COM | $70,335,000 | 2,250,000 |
| EYEPOINT INC | EYPT | COM NEW | $65,780,000 | 4,600,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.